A Pilot, Randomized, Placebo-Controlled Trial Evaluating the Treatment of Premenstrual Dysphoric Disorder With Oral Contraceptives in Bipolar Disorder.
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2024 Status changed from recruiting to completed.
- 06 Sep 2023 Planned End Date changed from 1 Nov 2023 to 30 Jun 2024.
- 06 Sep 2023 Planned primary completion date changed from 1 Nov 2023 to 31 Mar 2024.